Comparison · NCT02134353-a22df19f
Experimental Arm A vs Arm B - Control: The Incidence of Pulmonary Exacerbations
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Experimental Arm A vs Arm B - Control: The Incidence of Pulmonary Exacerbations. Trial comparisons, record NCT02134353-a22df19f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02134353-a22df19f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.134 | 0.0943 | 0.187 | wilson | |
| Risk in group 2 | 0.136 | 0.096 | 0.188 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00154 | -0.0672 | 0.0644 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.61 | 1.6 | log | |
| Odds ratio, group 1 over group 2 | 0.987 | 0.565 | 1.72 | log | |
| Number needed to treat, for one fewer participant with the outcome on Experimental Arm A than on Arm B - Control | 648 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Experimental Arm A | Active treatment. Inhaled Mannitol~Inhaled mannitol: Inhaled mannitol 400 mg BD for 26 weeks | 28 | 209 | OG000 |
| Group 2 | Arm B - Control | Arm B~Control BD (mannitol 50mg) for 26 weeks | 29 | 214 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- The Incidence of Pulmonary Exacerbations
- Description
To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is superior to control for decreasing incidence of protocol defined pulmonary exacerbations, where incidence is defined as the proportion of subjects with 1 or more exacerbation during the 26 week period.
- Time frame
- 26 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
- NCT number
- NCT02134353
- Phases
- PHASE3
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled mannitol, Placebo Comparator: Arm B - Control
- Lead sponsor
- Syntara
- Results first posted
- 2020-09-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02134353?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02134353-a22df19f